{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "Dapagliflozin 5 mg",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Dapagliflozin 5 mg tablets administered orally once daily as an add-on to adjustable insulin therapy."
      },
      {
        "id": "arm_2",
        "name": "Dapagliflozin 10 mg",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Dapagliflozin 10 mg tablets administered orally once daily as an add-on to adjustable insulin therapy."
      },
      {
        "id": "arm_3",
        "name": "Placebo",
        "type": {
          "code": "Placebo Comparator Arm",
          "codeSystem": "USDM",
          "decode": "Placebo Comparator Arm"
        },
        "instanceType": "StudyArm",
        "description": "Matching placebo tablets administered orally once daily as an add-on to adjustable insulin therapy."
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_1"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_2"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_3"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_4"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_1",
        "epochId": "epoch_5",
        "elementIds": [
          "elem_5"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_2",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_6"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_7",
        "armId": "arm_2",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_7"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_8",
        "armId": "arm_2",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_8"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_9",
        "armId": "arm_2",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_9"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_10",
        "armId": "arm_2",
        "epochId": "epoch_5",
        "elementIds": [
          "elem_10"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_11",
        "armId": "arm_3",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_11"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_12",
        "armId": "arm_3",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_12"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_13",
        "armId": "arm_3",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_13"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_14",
        "armId": "arm_3",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_14"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_15",
        "armId": "arm_3",
        "epochId": "epoch_5",
        "elementIds": [
          "elem_15"
        ],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "Global Population",
        "instanceType": "StudyCohort",
        "characteristic": "Approximately 768 subjects randomized globally"
      },
      {
        "id": "cohort_2",
        "name": "Japan Cohort",
        "instanceType": "StudyCohort",
        "characteristic": "Approximately 160 subjects included from Japan to support population-specific analyses"
      }
    ],
    "studyElements": [
      {
        "id": "elem_1",
        "name": "Dapagliflozin 5 mg - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Dapagliflozin 5 mg during Screening"
      },
      {
        "id": "elem_2",
        "name": "Dapagliflozin 5 mg - Lead-in Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Dapagliflozin 5 mg during Lead-in Period"
      },
      {
        "id": "elem_3",
        "name": "Dapagliflozin 5 mg - Short-term Treatment Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Dapagliflozin 5 mg during Short-term Treatment Period"
      },
      {
        "id": "elem_4",
        "name": "Dapagliflozin 5 mg - Long-term Treatment Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Dapagliflozin 5 mg during Long-term Treatment Period"
      },
      {
        "id": "elem_5",
        "name": "Dapagliflozin 5 mg - Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Dapagliflozin 5 mg during Follow-up"
      },
      {
        "id": "elem_6",
        "name": "Dapagliflozin 10 mg - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Dapagliflozin 10 mg during Screening"
      },
      {
        "id": "elem_7",
        "name": "Dapagliflozin 10 mg - Lead-in Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Dapagliflozin 10 mg during Lead-in Period"
      },
      {
        "id": "elem_8",
        "name": "Dapagliflozin 10 mg - Short-term Treatment Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Dapagliflozin 10 mg during Short-term Treatment Period"
      },
      {
        "id": "elem_9",
        "name": "Dapagliflozin 10 mg - Long-term Treatment Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Dapagliflozin 10 mg during Long-term Treatment Period"
      },
      {
        "id": "elem_10",
        "name": "Dapagliflozin 10 mg - Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Dapagliflozin 10 mg during Follow-up"
      },
      {
        "id": "elem_11",
        "name": "Placebo - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo during Screening"
      },
      {
        "id": "elem_12",
        "name": "Placebo - Lead-in Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo during Lead-in Period"
      },
      {
        "id": "elem_13",
        "name": "Placebo - Short-term Treatment Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo during Short-term Treatment Period"
      },
      {
        "id": "elem_14",
        "name": "Placebo - Long-term Treatment Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo during Long-term Treatment Period"
      },
      {
        "id": "elem_15",
        "name": "Placebo - Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo during Follow-up"
      }
    ],
    "summary": {
      "armCount": 3,
      "cellCount": 15,
      "cohortCount": 2,
      "elementCount": 15
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Double Blind",
        "codeSystem": "USDM",
        "decode": "Double Blind"
      },
      "maskedRoles": [
        "Subject",
        "Investigator",
        "Outcome Assessor",
        "Caregiver"
      ],
      "randomizationType": {
        "code": "Randomized",
        "codeSystem": "USDM",
        "decode": "Randomized"
      },
      "allocationRatio": {
        "ratio": "1:1:1"
      },
      "stratificationFactors": [
        "Current use of CGM (Yes vs No)",
        "Method of insulin administration (MDI vs CSII)",
        "Baseline HbA1c (7.5% to <9.0% vs 9.0% to 10.5%)"
      ],
      "controlType": {
        "code": "Placebo Control",
        "codeSystem": "USDM",
        "decode": "Placebo Control"
      },
      "armIds": [
        "arm_1",
        "arm_2",
        "arm_3"
      ],
      "cohortIds": [
        "cohort_1",
        "cohort_2"
      ],
      "therapeuticAreas": [
        "Endocrinology",
        "Metabolism"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Double Blind",
        "maskedRoles": [
          "Subject",
          "Investigator",
          "Outcome Assessor",
          "Caregiver"
        ]
      },
      "randomization": {
        "type": "Randomized",
        "allocationRatio": "1:1:1",
        "stratificationFactors": [
          "Current use of CGM (Yes vs No)",
          "Method of insulin administration (MDI vs CSII)",
          "Baseline HbA1c (7.5% to <9.0% vs 9.0% to 10.5%)"
        ]
      },
      "controlType": "Placebo",
      "therapeuticAreas": [
        "Endocrinology",
        "Metabolism"
      ]
    },
    "arms": [
      {
        "name": "Dapagliflozin 5 mg",
        "type": "Experimental Arm",
        "description": "Dapagliflozin 5 mg tablets administered orally once daily as an add-on to adjustable insulin therapy.",
        "isTitration": false,
        "doseEpochs": null
      },
      {
        "name": "Dapagliflozin 10 mg",
        "type": "Experimental Arm",
        "description": "Dapagliflozin 10 mg tablets administered orally once daily as an add-on to adjustable insulin therapy.",
        "isTitration": false,
        "doseEpochs": null
      },
      {
        "name": "Placebo",
        "type": "Placebo Comparator",
        "description": "Matching placebo tablets administered orally once daily as an add-on to adjustable insulin therapy.",
        "isTitration": false,
        "doseEpochs": null
      }
    ],
    "cohorts": [
      {
        "name": "Global Population",
        "characteristic": "Approximately 768 subjects randomized globally"
      },
      {
        "name": "Japan Cohort",
        "characteristic": "Approximately 160 subjects included from Japan to support population-specific analyses"
      }
    ],
    "epochs": [
      {
        "name": "Screening",
        "description": "Initial eligibility assessment"
      },
      {
        "name": "Lead-in Period",
        "description": "8-week period to optimize diabetes management and assess baseline glucose variability; no study medication provided."
      },
      {
        "name": "Short-term Treatment Period",
        "description": "24-week double-blind treatment period."
      },
      {
        "name": "Long-term Treatment Period",
        "description": "28-week subject- and site-blinded treatment period (total 52 weeks of treatment)."
      },
      {
        "name": "Follow-up",
        "description": "4-week post-treatment follow-up visit (Week 56)."
      }
    ]
  }
}